Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CVSI OTCMKTS:GLUC NASDAQ:GTBP NASDAQ:PPBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.04+1.7%$0.03$0.02▼$0.06$6.65M0.61145,055 shs50,681 shsGLUCGlucose Health$0.11+0.5%$0.10$0.08▼$0.38$1.84M1.796,579 shs400 shsGTBPGT Biopharma$1.81-2.7%$2.62$1.72▼$4.10$6.09M1.33105,373 shs38,748 shsPPBTPurple Biotech$2.17+0.5%$2.46$2.00▼$13.95$5.59M0.49263,223 shs30,777 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences+1.67%+3.10%-3.17%+35.56%-29.34%GLUCGlucose Health+0.52%+8.72%+3.92%+13.43%-69.95%GTBPGT Biopharma-2.69%-12.14%-41.61%-22.32%-30.65%PPBTPurple Biotech+0.46%-6.87%-9.58%-6.47%+216,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVSICV Sciences0.1166 of 5 stars0.03.00.00.00.60.00.0GLUCGlucose HealthN/AN/AN/AN/AN/AN/AN/AN/AGTBPGT Biopharma2.0086 of 5 stars3.84.00.00.00.00.00.6PPBTPurple Biotech2.2485 of 5 stars3.55.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVSICV Sciences 0.00N/AN/AN/AGLUCGlucose Health 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00507.73% UpsidePPBTPurple Biotech 3.00Buy$33.001,420.74% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVSICV Sciences$15.70M0.43N/AN/A$0.01 per share3.66GLUCGlucose Health$380K4.86N/AN/AN/A∞GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/APPBTPurple BiotechN/AN/AN/AN/A$12.73 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVSICV Sciences-$2.39MN/A0.00∞N/A-12.25%-89.43%-22.75%N/AGLUCGlucose Health-$320K-$0.03N/A∞N/A-82.29%N/AN/AN/AGTBPGT Biopharma-$13.16M-$5.69N/AN/AN/AN/A-1,033.08%-223.20%8/13/2025 (Estimated)PPBTPurple Biotech-$7.24M-$2.62N/AN/AN/AN/A-17.84%-15.44%8/15/2025 (Estimated)Latest GLUC, CVSI, GTBP, and PPBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025N/APPBTPurple Biotech-$0.21N/AN/AN/AN/AN/A8/13/2025Q2 2025GTBPGT Biopharma-$0.68N/AN/AN/AN/AN/A5/21/2025Q1 2025PPBTPurple BiotechN/A-$0.17N/A-$0.17N/AN/A5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVSICV SciencesN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVSICV Sciences0.261.140.30GLUCGlucose HealthN/AN/AN/AGTBPGT BiopharmaN/A0.730.73PPBTPurple BiotechN/A2.722.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVSICV SciencesN/AGLUCGlucose HealthN/AGTBPGT Biopharma8.15%PPBTPurple Biotech9.64%Insider OwnershipCompanyInsider OwnershipCVSICV Sciences3.80%GLUCGlucose HealthN/AGTBPGT Biopharma3.40%PPBTPurple Biotech2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVSICV Sciences70184.79 million177.77 millionNot OptionableGLUCGlucose Health147,00017.41 millionN/ANot OptionableGTBPGT Biopharma83.27 million3.16 millionNo DataPPBTPurple Biotech202.59 million2.51 millionOptionableGLUC, CVSI, GTBP, and PPBT HeadlinesRecent News About These CompaniesPurple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025July 23, 2025 | globenewswire.comPurple Biotech Stock Price History - Investing.comJuly 8, 2025 | investing.comPurple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual CongressJune 23, 2025 | globenewswire.comPurple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck CancerJune 17, 2025 | finance.yahoo.comPurple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody PlatformJune 4, 2025 | finance.yahoo.comH.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy RatingJune 1, 2025 | msn.comPurple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | finanznachrichten.dePurple Biotech Reports First Quarter 2025 Financial ResultsMay 21, 2025 | globenewswire.comPurple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial ExcellenceMay 13, 2025 | nasdaq.comPurple Biotech appoints Shai Lankry as new CFOMay 13, 2025 | investing.comPurple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | finanznachrichten.dePurple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | globenewswire.comPurple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic CancerApril 30, 2025 | tipranks.comPurple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck CancersApril 28, 2025 | globenewswire.comPurple Biotech announces publication of study on potential of NT219April 17, 2025 | markets.businessinsider.comPurple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research MeetingMarch 28, 2025 | finance.yahoo.comPurple Biotech Unveils Updated Oncology Pipeline ProgressMarch 18, 2025 | tipranks.comPurple Biotech Reports Positive Clinical Trial Results for CM24 and NT219, Advancing to Phase 2 StudiesMarch 12, 2025 | nasdaq.comPurple Biotech reports Q4 EPS (26c) vs. ($3.80) last yearMarch 10, 2025 | markets.businessinsider.comPurple Biotech sees cash runway into mid-2026March 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLUC, CVSI, GTBP, and PPBT Company DescriptionsCV Sciences OTCMKTS:CVSI$0.04 +0.00 (+1.67%) As of 08/1/2025 03:56 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.Glucose Health OTCMKTS:GLUC$0.11 +0.00 (+0.47%) As of 08/1/2025 03:53 PM EasternGlucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.GT Biopharma NASDAQ:GTBP$1.81 -0.05 (-2.69%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.86 +0.05 (+2.76%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Purple Biotech NASDAQ:PPBT$2.17 +0.01 (+0.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.15 -0.02 (-1.11%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
